Ind Swift Laboratories Ltd Stock Price Today (NSE: INDSWFTLAB)
Fundamental Score
Ind Swift Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Ind Swift Laboratories Ltd share price today is ₹131.43, up +0.97% on NSE/BSE as of 30 March 2026. Ind Swift Laboratories Ltd (INDSWFTLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹787.55 (Cr). The 52-week high for INDSWFTLAB share price is ₹151.98 and the 52-week low is ₹68.72. At a P/E ratio of 26.57x, INDSWFTLAB is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 0.18% and a debt-to-equity ratio of 0.02.
Ind Swift Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Ind Swift Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Ind Swift Laboratories Share Price Analysis: A ROCE Efficiency Perspective
One crucial factor influencing pharmaceutical companies today is the increasing scrutiny on capital allocation efficiency, with investors prioritizing firms demonstrating superior returns on invested capital. This analysis focuses on the "Ind Swift Laboratories share price" and its financial performance, specifically its Return on Capital Employed (ROCE). The current share price stands at ₹132.199997, accompanied by a Price-to-Earnings (PE) ratio of 26.57 and a ROCE of just 0.78%. This analysis forms part of a larger, 80-parameter fundamental audit verified by Sweta Mishra.
The low ROCE figure of 0.78% warrants a deeper investigation. ROCE, measuring the profitability of a company relative to its capital employed, is a critical indicator of how effectively management is utilizing resources to generate profits. A low ROCE suggests that Ind Swift Laboratories Ltd is not efficiently deploying its capital. This contrasts sharply with sector leaders who have established operational excellence and pricing power.
Compared to its peers, such as Mankind Pharma Ltd, the disparity becomes more apparent. While we observe that Mankind Pharma Ltd has demonstrated strong management quality, efficient operations, and therefore better shareholder returns, Ind Swift Laboratories Ltd appears to be struggling in this regard. Lower ROCE can be attributed to factors like inefficient working capital management, high operating costs, or suboptimal investment decisions. This analysis makes no claims or assumptions on management quality, but makes purely observational statements on the data.
The 0.78% ROCE also impacts the company's moat, or competitive advantage. A higher ROCE often indicates a stronger moat, as it reflects the company's ability to generate profits that are difficult for competitors to replicate. With such a low ROCE, Ind Swift Laboratories Ltd may find it challenging to maintain a strong competitive position in the long term. Sustained low ROCE figures can erode investor confidence, impacting future growth prospects. It's essential to monitor this metric closely, along with other key financial indicators, to assess the company's long-term value creation potential.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ind Swift Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INDSWFTLAB across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (16.66%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (1848.78%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (1176.25%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (15.79% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (15.81% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Cash Generation (₹148.79 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (0.18%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.78%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Limited Growth History (-6.35% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (1.17x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Ind Swift Laboratories Ltd Financial Statements
Comprehensive financial data for Ind Swift Laboratories Ltd including income statement, balance sheet and cash flow
About INDSWFTLAB (Ind Swift Laboratories Ltd)
Ind Swift Laboratories Ltd is a dynamic pharmaceutical entity carving its niche in the global healthcare landscape. With a steadfast commitment to innovation and quality, the compa...ny dedicates its resources to the research, development, and production of a diverse portfolio of pharmaceutical products. Its activities are deeply rooted in scientific rigor, with a focus on creating effective and accessible medications for a range of therapeutic needs. By combining advanced technologies and skilled personnel, Ind Swift Laboratories strives to address pressing health challenges and improve patient outcomes worldwide. The company stands as a testament to the power of dedicated pharmaceutical research in improving global health. The core business of Ind Swift Laboratories revolves around the creation of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished formulations, contributing to a comprehensive approach to drug development and manufacturing. The company strategically markets these products both domestically and internationally, reaching healthcare providers and patients across different regions. They have a strong emphasis on the manufacturing process, as the creation of APIs requires the utmost control. They're committed to high quality ingredients to ensure the safety and efficacy of its medicinal products. Ind Swift Laboratories is not just producing pharmaceuticals, but rather, is actively contributing to global healthcare solutions through its expanded reach and market strategy. Ind Swift Laboratories' dedication goes beyond simple manufacturing; they operate as an innovative force, pushing the boundaries of pharmaceutical science. This commitment is evident in its expanding portfolio of APIs, which caters to a broad spectrum of therapeutic areas. This includes treatments for cardiovascular conditions, diabetes, and a host of other ailments, demonstrating its commitment to addressing a wide range of health concerns. Through tireless effort and a focus on continuous improvement, Ind Swift Laboratories seeks to develop novel solutions that contribute to a healthier future. This dedication to improving the lives of individuals through innovative pharmaceuticals is the driving force behind Ind Swift Laboratories' growth and success.
Company Details
Key Leadership
Corporate Events
INDSWFTLAB Share Price: Frequently Asked Questions
What is the current share price of Ind Swift Laboratories Ltd (INDSWFTLAB)?
As of 30 Mar 2026, 12:04 pm IST, Ind Swift Laboratories Ltd share price is ₹131.43. The INDSWFTLAB stock has a market capitalisation of ₹787.55 (Cr) on NSE/BSE.
Is INDSWFTLAB share price Overvalued or Undervalued?
INDSWFTLAB share price is currently trading at a P/E ratio of 26.57x, compared to the industry average of 31.77x. Based on this relative valuation, the Ind Swift Laboratories Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of INDSWFTLAB share price?
The 52-week high of INDSWFTLAB share price is ₹151.98 and the 52-week low is ₹68.72. These values are updated daily from NSE/BSE price data.
What factors affect the Ind Swift Laboratories Ltd share price?
Key factors influencing INDSWFTLAB share price include quarterly earnings growth (Sales Growth: 1176.25%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Ind Swift Laboratories Ltd a good stock for long-term investment?
Ind Swift Laboratories Ltd shows a 5-year Profit Growth of 15.81% and an ROE of 0.18%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing in INDSWFTLAB shares.
How does Ind Swift Laboratories Ltd compare with its industry peers?
Ind Swift Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare INDSWFTLAB share price P/E of 26.57x and ROE of 0.18% against the industry averages to determine competitive standing.
What is the P/E ratio of INDSWFTLAB and what does it mean?
INDSWFTLAB share price has a P/E ratio of 26.57x compared to the industry average of 31.77x. Investors pay ₹27 for every ₹1 of annual earnings.
How is INDSWFTLAB performing according to Bull Run's analysis?
INDSWFTLAB has a Bull Run fundamental score of 42.2/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does INDSWFTLAB belong to?
INDSWFTLAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Ind Swift Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for INDSWFTLAB?
INDSWFTLAB has an ROE of 0.18%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Ind Swift Laboratories Ltd generates profits from shareholders capital.
How is INDSWFTLAB debt-to-equity ratio and what does it indicate?
INDSWFTLAB has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk.
What is INDSWFTLAB dividend yield and is it a good dividend stock?
INDSWFTLAB offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Ind Swift Laboratories Ltd shares.
How has INDSWFTLAB share price grown over the past 5 years?
INDSWFTLAB has achieved 5-year growth rates of: Sales Growth -6.35%, Profit Growth 15.81%, and EPS Growth 15.79%.
What is the promoter holding in INDSWFTLAB and why does it matter?
Promoters hold 39.50% of INDSWFTLAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Ind Swift Laboratories Ltd.
What is INDSWFTLAB market capitalisation category?
INDSWFTLAB has a market capitalisation of ₹788 crores, placing it in the Small-cap category.
How volatile is INDSWFTLAB stock?
INDSWFTLAB has a beta of N/A. A beta > 1 suggests the Ind Swift Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is INDSWFTLAB operating profit margin trend?
INDSWFTLAB has a 5-year average Operating Profit Margin (OPM) of 16.66%, indicating the company's operational efficiency.
How is INDSWFTLAB quarterly performance?
Recent quarterly performance shows Ind Swift Laboratories Ltd YoY Sales Growth of 1176.25% and YoY Profit Growth of 1848.78%.
What is the institutional holding pattern in INDSWFTLAB?
INDSWFTLAB has FII holding of 14.80% and DII holding of 0.68%. Significant institutional holding often suggests professional confidence in the Ind Swift Laboratories Ltd stock.